Vote Scores

Home / Companies / Ironwood Pharmaceuticals, Inc. / 10 Jun 2025

Meeting · year to 30 June 2025251 filers reporting

Ironwood Pharmaceuticals, Inc.: meeting of 10 Jun 2025

Votes reported on Form N-PX, item by item

251 Form N-PX filers reported votes at the Ironwood Pharmaceuticals, Inc. meeting of 10 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

9 nominees; 98.2% of reported votes for; 6 filers withheld from or voted against at least one nominee.

1,449 vote records from 89 filers. 1 of the 89 filers that marked the item either way voted against management.

98.9% for0.0% against1.1% other1.1% against management89 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

358 vote records from 250 filers. 15 of the 240 filers that marked the item either way voted against management. 10 filers reported this item without a management mark.

90.4% for6.0% against3.6% other6.3% against management250 filers94.5% for0.9% against4.6% other0.9% against management122,226,297 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

161 vote records from 89 filers. 0 of the 89 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management89 filers100.0% for0.0% against0.0% against management37,155,006 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalNo reportAgainst *No report
State Street and SPDRForForFor
Franklin TempletonForForFor
InvescoForForFor
EquitableForForFor
Charles SchwabForForFor
ProShares and ProFundsForForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertForForFor
J.P. MorganForForFor
Goldman SachsForForFor
WisdomTreeForForFor
PGIM and PrudentialAbstain or withhold *ForFor
Northern Trust and FlexSharesForForFor
SEIForForFor
T. Rowe PriceForForFor
Lincoln FinancialForForFor
VoyaForForFor
Russell InvestmentsForForFor
NationwideForForFor
Victory CapitalForForFor
Brighthouse FundsForForFor
Guggenheim and RydexForForFor
Columbia ThreadneedleForForFor
BNY MellonNo reportForNo report
PrincipalForForFor
Pacific Life fundsForForFor
Global XForForFor
Federated HermesForForFor
AllianceBernsteinNo reportForNo report
DWSForForFor
PIMCONo reportForNo report
AllspringNo reportForNo report
Neuberger BermanNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Ironwood Pharmaceuticals, Inc. meeting?

251 Form N-PX filers reported votes at the meeting of 10 Jun 2025. On say-on-pay, 15 of 240 voted against management (6.3%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Ironwood Pharmaceuticals, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Ironwood Pharmaceuticals, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Ironwood Pharmaceuticals, Inc. with a meeting date within three days of 10 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.